CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

Core Insights - CRISPR Therapeutics reported a second-quarter 2025 loss of $2.40 per share, wider than the previous year's loss of $1.49, primarily due to a $96.3 million expense related to a collaboration with Sirius Therapeutics [1][6] - Adjusted loss, excluding special items, was $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47 [2] - Total revenues for the quarter were $0.89 million, significantly below the Zacks Consensus Estimate of $6.6 million, compared to $0.5 million in the same period last year [2] Financial Performance - CRISPR Therapeutics' stock fell over 8% in after-market trading following the wider-than-expected loss, continuing the downward trend in pre-market trading [3] - The stock has increased by 51% year-to-date, outperforming the industry growth of 2% [3] - Research and development expenses decreased by 13% year-over-year to $69.9 million, while general and administrative expenses fell by 3% to $18.9 million [8] Product Development and Sales - Casgevy, a CRISPR/Cas9 gene-edited therapy developed in partnership with Vertex Pharmaceuticals, saw sales of $30.4 million in Q2, up from $14.2 million in the previous quarter [5][6] - Over 75 treatment centers have been activated globally for Casgevy, with approximately 115 patients completing their first cell collection since its launch [6][7] - The company is advancing its CAR-T and in-vivo therapy pipelines, with updates expected later this year [10][11] Pipeline Expansion - CRISPR Therapeutics is developing two next-generation CAR-T therapy candidates, CTX112 and CTX131, currently in phase I/II studies [10] - The company is also studying in-vivo candidates CTX310 and CTX320, with promising early data showing significant reductions in LDL and triglyceride levels [11] - A collaboration with Sirius Therapeutics has diversified the pipeline into RNA therapeutics, with a focus on the investigational siRNA candidate SRSD107 [12][13] Financial Position - As of June 30, 2025, CRISPR Therapeutics had cash and marketable securities totaling $1.72 billion, down from $1.86 billion at the end of March 2025 [9]